Inventor · disambiguated record
Charles K. Stover
Also filed as: STOVER CHARLES · STOVER CHARLES K · STOVER CHARLES KENDALL
17 granted patents·11 pending applications·330 citations·filing 1992–2025
94Inventor score
Top patents by PatentIndex Score
28 records- 0190US11203633B2Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas pervMEDIMMUNE LTD·Filed 2020·Granted Dec 21, 2021·2 cites·25 claims
- 0290US6180111B1Vaccine delivery systemUNIV MARYLAND·Filed 1998·Granted Jan 30, 2001·104 cites·19 claims
- 0389US10844114B2Anti-Pseudomonas Psl binding molecules and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Nov 24, 2020·3 cites·21 claims
- 0489US9580509B2Multispecific and multivalent binding proteins and uses thereofMEDIMMUNE LLC·Filed 2012·Granted Feb 28, 2017·9 cites·18 claims
- 0587US10370436B2Anti-pseudomonas Psl binding molecules and uses thereofMEDIMMUNE LTD·Filed 2016·Granted Aug 6, 2019·5 cites·5 claims
- 0683US9403901B2Anti-pseudomonas Psl binding molecules and uses thereofDIGIANDOMENICO ANTONIO·Filed 2012·Granted Aug 2, 2016·9 cites·14 claims
- 0783US5583038ABacterial expression vectors containing DNA encoding secretion signals of lipoproteinsMEDIMMUNE INC·Filed 1992·Granted Dec 10, 1996·98 cites·31 claims
- 0882US11117956B2Anti-O1 antibodies and uses thereofMEDIMMUNE LLC·Filed 2017·Granted Sep 14, 2021·3 cites·25 claims
- 0981US10597439B2Combination therapies using anti-pseudomonas PSL and PCRV binding moleculesMEDIMMUNE LLC·Filed 2012·Granted Mar 24, 2020·4 cites·7 claims
- 1080US11447542B2Anti-O2 antibodies and uses thereofMEDIMMUNE LLC·Filed 2017·Granted Sep 20, 2022·1 cites·21 claims
- 1180US2024383969A1Anti-o1 antibodies and uses thereofMEDIMMUNE LLC·Filed 2024·Application pending·0 cites
- 1277US12428473B2Combination therapies using anti-pseudomonas PSL and PCRV binding moleculesMEDIMMUNE LTD·Filed 2021·Granted Sep 30, 2025·0 cites·20 claims
- 1376US10870710B2Synthetic oligosaccharide subunits of the Psl exopolysaccharide of pseudomonas aeruginosa and uses thereofMEDLMMUNE LTD·Filed 2018·Granted Dec 22, 2020·2 cites·7 claims
- 1474US12312397B2Anti-O2 antibodies and uses thereofMEDIMMUNE LLC·Filed 2022·Granted May 27, 2025·0 cites·15 claims
- 1573US12018068B2Anti-O1 antibodies and uses thereofMEDIMMUNE LLC·Filed 2021·Granted Jun 25, 2024·0 cites·23 claims
- 1673US2025368723A1Anti-o2 antibodies and uses thereofMEDIMMUNE LLC·Filed 2025·Application pending·0 cites
- 1772US5700683AVirulence-attenuating genetic deletions deleted from mycobacterium BCGPATHOGENESIS CORP·Filed 1995·Granted Dec 23, 1997·47 cites·57 claims
- 1872US2025243262A1Combination therapies using anti-pseudomonas psl and pcrv binding moleculesMEDIMMUNE LTD·Filed 2025·Application pending·0 cites
- 1969US2021130442A1Anti-pseudomonas psl binding molecules and uses thereofMEDIMMUNE LTD·Filed 2020·Application pending·0 cites
- 2060US5736367AVectors and prokaryotes which autocatalytically delete antibiotic resistanceMEDIMMUNE INC·Filed 1995·Granted Apr 7, 1998·27 cites·14 claims
- 2156US5679515AMycobacterial reporter strains and uses thereofPATHOGENESIS CORP·Filed 1994·Granted Oct 21, 1997·16 cites·38 claims
- 2251US2017073397A1MrkA Polypeptides, Antibodies, and Uses ThereofMEDIMMUNE LLC·Filed 2016·Application pending·0 cites
- 2348US2017114151A1Multispecific and multivalent binding proteins and uses thereofMEDIMMUNE LLC·Filed 2016·Application pending·0 cites
- 2448US2016115250A1Synthetic Oligosaccharide Subunits Of The PSL Exopolysaccharide Of Pseudomonas Aeruginosa And Uses ThereofMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 2547US2019062411A1Mrka polypeptides, antibodies, and uses thereofMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 2645US2002187160A1Vaccine delivery systemUNIV MARYLAND·Filed 2002·Application pending·0 cites
- 2745US2015284450A1Combination therapies using anti-pseudomonas psl and pcrv binding moleculesMEDIMMUNE LLC·Filed 2013·Application pending·0 cites
- 2836US2017183397A1Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereofMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →